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Introduction {#sec1}
============

The discovery that transcription factors (TFs) can convert somatic cells into both specialized and induced pluripotent stem cells (iPSCs) has revolutionized stem cell research and promises to have major clinical applications ([@bib17; @bib46]). Lineage-instructive TFs activate and repress tissue-specific genes by recognizing sequence-specific DNA consensus motifs contained within enhancers and promoters ([@bib30]). They establish gene regulatory networks (GRNs) of the novel gene expression program while dismantling those of the old program, involving the formation of feedforward, cross-inhibitory, and auto-regulatory loops ([@bib3; @bib8; @bib17; @bib21]). However, how these processes are coordinated and whether they recapitulate normal development remain unclear ([@bib42]), especially as neither TF-induced lineage conversions nor iPSC reprogramming appear to retrace normal developmental pathways ([@bib1; @bib12; @bib25; @bib42]).

Lineage-instructive TFs act through synergistic and cross-antagonistic interactions, are typically able to access closed chromatin ([@bib49]), preferentially target sites with specific histone mark combinations, and bind to either nucleosome-depleted or nucleosome-dense regions ([@bib37; @bib38; @bib43]). However, what establishes these chromatin configurations in the first place and what proportion of the incoming reprogramming factors interacts with pre-existing TF complexes are largely unknown. A major reason for these gaps in our knowledge is that cell conversion frequencies in most cell systems are low, complicating efforts to study early events in a time-resolved fashion.

An exception is the transdifferentiation of pre-B/B cells into macrophages induced by the leucine zipper-type TF C/EBPα, which is arguably the most efficient and rapid system described so far ([@bib4; @bib11; @bib45]). C/EBPβ, like C/EBPα, can likewise induce B cell transdifferentiation into macrophages ([@bib4; @bib45]), but the two factors also have non-redundant functions. Mice ablated for C/EBPα die shortly after birth because they lack granulocyte/macrophage progenitors (GMPs, precursors of neutrophil granulocytes and macrophages, two closely related myeloid cell types) as well as granulocytes, while C/EBPβ-knockout animals are fully viable but contain macrophages and B cells with functional defects ([@bib6; @bib39]). C/EBPα cooperates with PU.1 (Spi1) to regulate myeloid gene expression ([@bib16]), the two factors interact physically ([@bib33]), and a combination of C/EBPα and PU.1 converts fibroblast into macrophage-like cells ([@bib15]). The *Pu.1* gene encodes an Ets family TF specifically expressed in the early stages of hematopoiesis and its knockout generates mice that lack both myeloid and lymphoid cells ([@bib35]). Low-level expression of PU.1 in hematopoietic precursors induces B cell differentiation, whereas high levels favor myeloid differentiation ([@bib9]).

Here we have analyzed, in a time-resolved manner, how C/EBPα establishes a myeloid expression program in pre-B cells, and we found that it binds to both pre-existing enhancers occupied by PU.1 and de novo enhancers where it acts as a pioneer factor. Strikingly, the combined activation of these enhancer types, regulating the expression of nearby macrophage genes, recapitulates the activation of myeloid enhancers and associated genes during normal hematopoiesis.

Results {#sec2}
=======

C/EBPα Induces High-Level Expression of *Pu.1* and *Cebpb* {#sec2.1}
----------------------------------------------------------

To study how C/EBPα induces transdifferentiation, we used two pre-B cell lines that express an inducible C/EBPαER fusion protein tagged with either human CD4 (hCD4; C11 cells) or GFP (C10 cells). In both lines, treatment with 17 beta-estradiol (β-Est) shuttles C/EBPαER into the nucleus and induces the formation of macrophage-like cells within 2 to 3 days ([@bib4]). Importantly, C/EBPα mRNA levels in C10 cells at 0 hr post-induction (hpi) or 24 hpi did not exceed C/EBPα levels observed in primary macrophages (MΦ) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). To monitor two important myeloid regulators known to cooperate with C/EBPα, we tested the expression levels of *Cebpb* and *Pu.1*. These genes were expressed at low to intermediate levels in pre-B cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and became upregulated within 3--12 hpi ([Figure 1](#fig1){ref-type="fig"}A). As C10 cells become transgene independent 24 hpi ([@bib4]), i.e., before the expression of endogenous C/EBPα ([Figure 1](#fig1){ref-type="fig"}A), we determined whether the rapid activation of C/EBPβ and PU.1 is necessary for transdifferentiation. We generated C11 cells stably expressing a short hairpin RNA (shRNA) against C/EBPβ, PU.1, or both. Cells were induced with β-Est and analyzed by fluorescence-activated cell sorting (FACS) for the presence of Cd19 and Mac-1 (CD11b) at different days thereafter. At 3 days post-induction (dpi), the knockdown of C/EBPβ and of PU.1 resulted in a 35% and 50% reduction in the formation of Mac-1^+^Cd19^−^ cells, respectively, while deleting both factors further enhanced the effect. At 7 dpi, Mac-1 expression in shC/EBPβ cells caught up with wild-type levels, whereas cells expressing shPU.1 exhibited extensive cell death ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}C). These data show that C/EBPα rapidly upregulates *Pu.1* and *Cebpb,* that PU.1 is necessary to establish the myeloid GRN, and that C/EBPβ plays a more minor role.

A Limited Set of Sites Stably Bound by C/EBPα Correlates with the Upregulation of Macrophage Genes {#sec2.2}
--------------------------------------------------------------------------------------------------

To explore the mechanism by which C/EBPα turns on the myeloid program in pre-B cells, we treated C10 cells for different times with β-Est and performed chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) experiments, using antibodies to C/EBPα, C/EBPβ, and PU.1 ([Table S1](#mmc2){ref-type="supplementary-material"} gives a summary of ChIP-seq results and peak calling). A total of 54,198 non-redundant C/EBPα-enriched regions could be detected during the time course of which 10,849 sites were stably bound (i.e., up to 48 hpi, [Table S2](#mmc3){ref-type="supplementary-material"}), whereas the remaining sites were transiently bound. Genes nearest stable binding sites, but not transient sites, were enriched for upregulated genes ([Figure S1](#mmc1){ref-type="supplementary-material"}D). In addition, using a sliding-window approach, we observed that 70% of upregulated genes were localized within 100 kb of a stable C/EBPα-binding site, whereas no such enrichment was seen for downregulated genes ([Figure 1](#fig1){ref-type="fig"}C). Motif analysis of the stable sites in 48-hpi cells (hereafter referred to as induced macrophages or iMΦ) showed strong enrichment for consensus motifs of C/EBP and PU.1. The same sites also were enriched for AP-1 (Jun and Fos) and RUNX motifs, as previously reported ([Figure 1](#fig1){ref-type="fig"}D; [@bib19]) and more weakly enriched for EBF1 ([Figure 1](#fig1){ref-type="fig"}D; also see [Figure 3](#fig3){ref-type="fig"}). The majority of stable C/EBPα sites were co-occupied by C/EBPβ and PU.1 in iMΦ, and ∼40% of these were pre-bound by PU.1 in pre-B cells, however, showing lower intensity signals ([Figure 1](#fig1){ref-type="fig"}E). Low-intensity signals in pre-B cells also were detectable for C/EBPβ, reflecting its low-level expression, as well as for C/EBPα ([Figure S1](#mmc1){ref-type="supplementary-material"}E), suggesting some leakiness of the transgene.

A total of 10,849 C/EBPα sites were detected in iMΦ and 62,814 in bone-marrow-derived macrophages (MΦ) ([@bib51]), showing 9,288 common sites ([Figure 1](#fig1){ref-type="fig"}F). The larger number of sites in MΦ compared to iMΦ cannot be explained by a higher sequencing depth ([Table S1](#mmc2){ref-type="supplementary-material"}). However, these differences became smaller when the numbers of associated genes were compared as follows: C/EBPα sites combined with 5,849 and 14,078 genes in iMΦ and MΦ, respectively, and shared 5,252 genes ([Figure S1](#mmc1){ref-type="supplementary-material"}F). The shared gene set was enriched for genes that became upregulated during transdifferentiation of primary B cells into macrophages ([@bib12]), whereas the gene set unique for MΦ (8,826) was actually depleted ([Figure S1](#mmc1){ref-type="supplementary-material"}G). In addition, shared upregulated genes were enriched for gene ontology (GO) terms associated with myeloid function, while upregulated genes unique for MΦ were not ([Figure S1](#mmc1){ref-type="supplementary-material"}H). The induced rapid and efficient conversion of pre-B cells into highly motile, aggregating, and phagocytic macrophages within 51 hr ([Movie S1](#mmc6){ref-type="supplementary-material"}; [@bib4]) further supports the interpretation that C/EBPα binds to a core set of enhancers in iMΦ required for myeloid cell specification.

The binding of C/EBPα, C/EBPβ, and PU.1 in induced C10 cells and of C/EBPα in primary MΦ is illustrated for the promoter and the −14-kb URE enhancer of the *Pu.1* gene ([@bib48]), for three putative enhancers of *Cebpb* ([Figure 1](#fig1){ref-type="fig"}G), as well as for putative enhancers of *Fos* and *Il1b* ([Figure S1](#mmc1){ref-type="supplementary-material"}I). (Genomic coordinates of these and other regions are described in [Table S3](#mmc4){ref-type="supplementary-material"}.) Together, our data suggest that C/EBPα combined with C/EBPβ and PU.1 activates a core set of enhancers, shared between the cell line and primary macrophages, required to induce macrophage specification.

Prospective Myeloid Enhancers in Pre-B Cells Fall into Two Broad Classes {#sec2.3}
------------------------------------------------------------------------

To characterize the epigenetic status of prospective myeloid regulatory regions in pre-B cells, we performed ChIP-seq experiments for histone modifications characteristic of poised (H3K4Me1), active (H3K27Ac, P300), and repressed enhancers (H3K27Me3) ([@bib7; @bib31]), and we analyzed levels of these marks at C/EBPα sites away from the transcription start site (TSS), representing putative enhancers ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We observed two broad classes of prospective myeloid enhancers in pre-B cells as follows: (1) pre-existing enhancers that were decorated with H3K4Me1, H3K27Ac, and P300 and depleted for H3K27Me3 ([Figure 2](#fig2){ref-type="fig"}A); and (2) de novo enhancers that lacked any of the active enhancer marks but were instead often decorated with H3K27Me3 ([Figure 2](#fig2){ref-type="fig"}A). Similar results were obtained by performing ChromHMM analysis ([Figure S2](#mmc1){ref-type="supplementary-material"}C; [@bib14]) as an independent analytical approach demonstrating that pre-existing enhancers are enriched for activation marks, whereas de novo enhancers are depleted for activation marks and enriched for H3K27Me3 ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Approximately two-thirds of the pre-existing enhancers were bound by PU.1 and exhibited high levels of activation marks compared to sites not bound by PU.1 ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Importantly, we confirmed the presence of pre-existing- and de-novo-type enhancers in primary B cells by using recently published ChIP-seq datasets ([Figure 2](#fig2){ref-type="fig"}B; [@bib19; @bib27]). Furthermore, we confirmed binding of C/EBPα to selected pre-existing enhancers of the *Pu.1*, *Cebpb*, *Il1b*, *Ehd1*, and *Ifngr2* genes and to de novo enhancers of the *Mmp12*, *Cd14*, *Gbe1*, *Fos*, and *Fgd4* genes in primary pre-B cells induced to transdifferentiate ([Figures 2](#fig2){ref-type="fig"}C and 2D; [@bib10]).

To determine whether the enhancer activation state in pre-B cells correlates with gene expression, we first analyzed the promoter configuration of adjacent genes and found the following: 73% of the pre-existing enhancers paired with active promoters (as defined by the sole presence of H3K4Me3), 7% were decorated with inactive promoters (H3K27Me3 or no marks), and 20% were decorated with promoters containing a bivalent domain (H3K4Me3 and H3K27Me3) ([Figure 2](#fig2){ref-type="fig"}E). In contrast, only 36% of de novo enhancers paired with active promoters, 44% with inactive promoters, and 20% with bivalent promoters ([Figures 2](#fig2){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}E). Based on these results, we re-defined pre-existing enhancers as those that combine with active promoters and de novo enhancers as those that pair with inactive promoters. As expected, genes associated with pre-existing enhancers already were expressed at significant levels in pre-B cells and primary pre-B cells ([@bib4; @bib12]), whereas genes associated with de novo enhancers only showed background expression levels ([Figure 2](#fig2){ref-type="fig"}F).

The finding that pre-B cells express genes associated with pre-existing enhancers predicts that PU.1 expression in cells devoid of PU.1 will selectively activate these genes. To test this, we expressed PU.1 in 3T3 fibroblasts ([Figure 2](#fig2){ref-type="fig"}G) and measured mRNA levels of a number of genes associated with either pre-existing or de novo enhancers. Supporting the hypothesis that PU.1 preferentially binds to pre-existing enhancers and activates associated genes, we observed that 6 of 11 pre-existing enhancer-associated genes tested were upregulated as compared to 2 of 10 de novo genes ([Figure 2](#fig2){ref-type="fig"}G; primer sequences are in [Table S4](#mmc5){ref-type="supplementary-material"}).

Together, our findings suggest that C/EBPα is capable of activating two broad classes of prospective myeloid enhancers in pre-B cells as follows: (1) pre-existing enhancers with active enhancer marks that are predominantly associated with expressed genes, and (2) de novo enhancers lacking such marks that are predominantly associated with silenced genes.

A Subset of Pre-existing Myeloid Enhancers Is Bound by the B Cell TF Ebf1 in Pre-B Cells {#sec2.4}
----------------------------------------------------------------------------------------

Our finding that motifs associated with the B cell TF Ebf1 are enriched in myeloid enhancers (see [Figure 1](#fig1){ref-type="fig"}D) prompted us to study their relevance in transdifferentiation. Analysis of the Ebf1 motif distribution shows that it is specifically enriched in pre-existing enhancers ([Figure 3](#fig3){ref-type="fig"}A). To test actual binding of Ebf1, we performed ChIP-seq experiments in pre-B cells yielding 6,627 Ebf1 peaks that were predominantly located in intergenic regions ([Figure 3](#fig3){ref-type="fig"}B) and enriched for EBF1, ETS (PU.1), and E2A motifs ([Figure 3](#fig3){ref-type="fig"}C). In line with the motif analysis, intersection of Ebf1-bound sites with the two types of myeloid enhancers showed 725 that were associated with pre-existing enhancers, but virtually none with de novo enhancers ([Figure 3](#fig3){ref-type="fig"}D).

To determine the functional state of the Ebf1-bound enhancers targeted by C/EBPα, we determined the kinetics of Ebf1 and C/EBPα binding as well as H3K27Ac decoration after induction of transdifferentiation. The heatmaps in [Figure 3](#fig3){ref-type="fig"}E show that, while C/EBPα binding already was observed after 3 hpi, the loss of Ebf1 binding was not detected until 48 hpi. However, H3K27Ac enrichment at these enhancers was maintained throughout the time course ([Figure 3](#fig3){ref-type="fig"}E), suggesting that the relevant enhancers remain active even after the loss of Ebf1. Examples of enhancers bound by Ebf1, C/EBPα, and PU.1 are shown in [Figure 3](#fig3){ref-type="fig"}F. This includes the 88-kb putative enhancer of *Cebpb* (see [Figure 1](#fig1){ref-type="fig"}G), as well as *Nfe2* and *Cd40* enhancers. In addition to enhancers bound by Ebf1, C/EBPα, and PU.1, 27% lack PU.1 binding, as exemplified by the −150-kb *Tgfbr2* putative enhancer ([Figure 3](#fig3){ref-type="fig"}F; additional examples are shown in [Figure S3](#mmc1){ref-type="supplementary-material"}A). Ebf1 binding to these regions was confirmed using an independent Ebf1 ChIP-seq dataset ([@bib40]; [Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Importantly, genes associated with putative Ebf1-C/EBPα-bound enhancers were upregulated during transdifferentiation ([Figure S3](#mmc1){ref-type="supplementary-material"}D).

In conclusion, a significant proportion of pre-existing myeloid enhancers targeted by C/EBPα in pre-B cells are bound by the B cell TF Ebf1. This finding raises the possibility that pre-existing myeloid enhancers act as bona fide B cell enhancers and that C/EBPα converts them into enhancers active in myeloid cells.

C/EBPα Acts Both as a Pioneer and as a Secondary Factor at Prospective Myeloid Enhancers {#sec2.5}
----------------------------------------------------------------------------------------

To study how the two enhancer types become activated, we determined the binding kinetics of PU.1, C/EBPα, and C/EBPβ. As expected, at pre-existing enhancers PU.1 was bound throughout the time course, whereas it was initially absent at de novo enhancers, gradually increasing after induction ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A). In contrast, C/EBPα binding showed a steeper increase at pre-existing than at de novo enhancers, with both converging at 48 hpi and the rate of C/EBPα binding kinetics correlating with the starting levels of H3K27Ac or H3K27Me3, respectively ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Finally, C/EBPβ occupancy increased steadily at the two enhancer types ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A).

The binding profiles observed predict that at de novo enhancers C/EBPα binds before PU.1. Indeed, ChIP-seq experiments with induced C10 cells at early time points (10, 30, and 60 min post-induction) showed that C/EBPα binds to 74% of de novo sites *before* PU.1 ([Figure 4](#fig4){ref-type="fig"}B). An example of a putative pre-existing enhancer bound by PU.1 first is shown for the *Tyrobp* gene; examples of de novo enhancers are the 24-kb site of *Tlr4*, the 65-kb enhancer of *Cebpb*, and the −16-kb site of *Ctsd* ([Figure 4](#fig4){ref-type="fig"}C).

To further study the interplay between PU.1 and C/EBPα, we knocked down PU.1 in pre-B cells ([Figure S4](#mmc1){ref-type="supplementary-material"}C), induced transdifferentiation for 3 and 24 hr, and analyzed C/EBPα binding at five pre-existing and five de novo enhancers. In control cells we observed higher binding of C/EBPα at 3 hpi for the pre-existing relative to the de novo enhancers. In addition, knockdown of PU.1 caused an initial decrease of C/EBPα binding at 3 hpi for both enhancer types on all loci tested ([Figures 4](#fig4){ref-type="fig"}D and 4E; primer sequences are in [Table S4](#mmc5){ref-type="supplementary-material"}). However, at 24 hpi, C/EBPα binding recovered to control levels or even above in 9 of 10 enhancers tested ([Figures 4](#fig4){ref-type="fig"}D and 4E). This suggests that C/EBPα binding at pre-existing enhancers does not strictly require PU.1, raising the possibility that C/EBPα can access closed chromatin (see also [Figures 2](#fig2){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}B).

To test this more directly, we performed micrococcal nuclease (Mnase) digestion experiments with chromatin isolated from pre-B cells and iMΦ cells and deep-sequenced nuclease-protected DNA. Average nucleosome profiles calibrated with sites uniquely bound by PU.1 revealed a nucleosome-depleted region (valley) flanked by two positioned nucleosomes ([Figure S4](#mmc1){ref-type="supplementary-material"}D) that confirmed an earlier report ([@bib19]). Pre-existing enhancers bound by PU.1 in pre-B cells showed a small valley that became more pronounced in iMΦ ([Figure 4](#fig4){ref-type="fig"}F). In contrast, de novo enhancers targeted by C/EBPα in pre-B cells were contained in a nucleosome-dense region that changed into a profile similar to that observed for pre-existing enhancers, although less pronounced, in iMΦ ([Figure 4](#fig4){ref-type="fig"}G). No ordered nucleosome patterns were obtained with profiles centered on random genomic positions ([Figure S4](#mmc1){ref-type="supplementary-material"}E).

Our data show that C/EBPα binds to a nucleosome-depleted region in pre-existing enhancers and to a nucleosome-dense region in de novo enhancers. These findings support the notion that C/EBPα can act as a pioneer factor.

The C/EBPα and PU.1 Binding Order Determines the Activation Kinetics of Adjacent Genes {#sec2.6}
--------------------------------------------------------------------------------------

To determine whether the epigenetic status of the two enhancer types in pre-B cells influences their subsequent activation kinetics, we analyzed enrichment levels of H3K4Me1, H3K27Ac, P300, and H3K27Me3 during transdifferentiation. As judged by P300 and H3K27Ac, pre-existing enhancers became hyper-activated, albeit mostly in a transient manner. In contrast, de novo enhancers became gradually activated, starting from background levels ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S5](#mmc1){ref-type="supplementary-material"}A). Both enhancer types followed a similar sequence of enhancer mark acquisition, consisting in P300 binding followed by H3K4Me1 and H3K27Ac decoration ([Figure 5](#fig5){ref-type="fig"}B). In contrast, the repressive H3K27Me3 decreased, predominantly on de novo enhancers ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}B). These findings are illustrated for the pre-existing 3-kb FIRE enhancer of the *Csf1r* gene and the de novo −16-kb enhancer of *Ctsd* ([Figure 5](#fig5){ref-type="fig"}D). Additional examples are shown in [Figure S5](#mmc1){ref-type="supplementary-material"}C.

To determine how the two types of prospective myeloid enhancers modulate the upregulation kinetics of adjacent genes, we interrogated gene expression data from C10 cells and primary pre-B cells induced to transdifferentiate ([@bib4; @bib12]). Pre-existing enhancer-associated genes started from low expression levels and became gradually upregulated ∼4-fold, while de novo enhancer-associated genes started from background levels and were upregulated ∼9-fold ([Figures 5](#fig5){ref-type="fig"}E, 5F, [S5](#mmc1){ref-type="supplementary-material"}D, and S5E).

In sum, the C/EBPα and PU.1 binding order determines the activation kinetics of targeted enhancers, with pre-existing enhancers becoming activated gradually from detectable base levels and de novo enhancers becoming activated more steeply and with a delay. These differences also are reflected in the activation kinetics of adjacent genes.

Pre-existing and De Novo Enhancers Are in an Active State in Distinct Hematopoietic Cell Types {#sec2.7}
----------------------------------------------------------------------------------------------

Are the pre-existing and de novo myeloid enhancers identified during transdifferentiation relevant for normal hematopoietic differentiation? To study this we determined their activation state in various types of immature and mature hematopoietic cells and interrogated expression data of associated genes during hematopoiesis ([@bib27]; see [Figure 6](#fig6){ref-type="fig"}A for the hematopoietic lineage tree and nomenclature used). Surprisingly, ∼58% of pre-existing enhancers already were active (i.e., marked by H3K27Ac) in long-term hematopoietic stem cells (LT-HSCs), and their proportion further increased in common myeloid and lymphoid progenitors (CMPs and CLPs, respectively), reaching ∼66% and ∼74% in terminally differentiated granulocytes (Gns) and MΦ, respectively ([Figures 6](#fig6){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}A). Moreover, a substantial fraction of pre-existing enhancers remained active in B cells (60%) but decreased in megakaryocyte-erythroid progenitors (MEPs), erythroid cells (Erys), and T cells (∼30%) ([Figures 6](#fig6){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}A). In contrast, activated de novo enhancers were essentially restricted to the myeloid compartment with 25%--28% being decorated with H3K27Ac in CMPs and GMPs and ∼40% in Gns and MΦs, while HSCs and multipotent progenitors (MPPs) showed lower percentages (7% and 14%) and MEPs, Erys, and B and T cells were essentially negative ([Figures 6](#fig6){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}A). Similar trends were observed for pre-existing and de novo enhancers marked with H3K4Me1 ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Heatmaps of the two enhancer types during the transition from short-term hematopoietic stem cells (ST-HSCs) to macrophages ([Figure 6](#fig6){ref-type="fig"}D) were remarkably similar to those of pre-B cells transdifferentiating into macrophages (see [Figure 5](#fig5){ref-type="fig"}A). In contrast, the two enhancer types were not activated in T cells ([Figure 6](#fig6){ref-type="fig"}E).

These findings are illustrated for the pre-existing −14-kb URE enhancer of *Pu.1* and the 88-kb putative enhancer of *Cebpb* ([Figure 6](#fig6){ref-type="fig"}F), which are bound by PU.1 ([Figure 1](#fig1){ref-type="fig"}G). A de novo enhancer is exemplified by the 65-kb enhancer of *Cebpb* ([Figure 6](#fig6){ref-type="fig"}F). Strikingly, mRNA levels of genes associated with pre-existing and de novo enhancers reflected enhancer activity during hematopoiesis using two independently derived datasets analyzed by either RNA-seq or expression arrays ([Figures 6](#fig6){ref-type="fig"}G, [S6](#mmc1){ref-type="supplementary-material"}C, and S6D; [@bib27; @bib12]). The arrays also showed that in normal macrophages the expression levels of genes associated with the two enhancer types nearly converged ([Figure S6](#mmc1){ref-type="supplementary-material"}D).

In conclusion, our data show that the majority of pre-existing enhancers targeted by C/EBPα during transdifferentiation are broadly active in hematopoietic stem cells, progenitors, and B cells, whereas de novo enhancers are largely restricted to the myeloid compartment.

The Activity of the Two Enhancer Types Reflect *Pu.1*, *Cebpa*, and *Cebpb* Expression during Hematopoiesis {#sec2.8}
-----------------------------------------------------------------------------------------------------------

How are the two enhancer types observed during C/EBPα-induced transdifferentiation controlled during normal hematopoiesis? To study this we analyzed the expression of *Pu.1*, *Cebpa*, and *Cebpb* during hematopoietic differentiation. *Pu.1* expression was found to closely correlate with that of pre-existing enhancers, *Pu.1* being broadly expressed in stem and progenitor cells and weakly in T cells, MEPs, and Erys ([Figure 7](#fig7){ref-type="fig"}A). Similar expression patterns were observed at the protein level with PU.1 reporter mice ([@bib2]). In turn, *Cebpa* was expressed mostly in the myeloid compartment where its levels were highest in GMPs ([Figure 7](#fig7){ref-type="fig"}A; [@bib44]), in agreement with the fact that mice lacking C/EBPα do not develop GMPs ([@bib50]). In contrast, *Cebpb* expression reached highest levels in macrophages and Gns ([Figure 7](#fig7){ref-type="fig"}A), suggesting that C/EBPβ takes over the role of C/EBPα in terminally differentiated myeloid cells. This interpretation agrees with the fact that macrophages from C/EBPβ-knockout mice have functional defects ([@bib6; @bib39]).

To test whether the *Cebpa* expression pattern reflects its binding specificity in the hematopoietic system, we analyzed the C/EBPα-binding sites identified in pre-existing and de novo enhancers in stem and progenitors cells and GMPs, as previously reported ([@bib18]). Strikingly, \<10% of prospective myeloid enhancers were bound by C/EBPα in the progenitors, while ∼80% of the sites were bound in GMPs and in primary macrophages ([Figure 7](#fig7){ref-type="fig"}B). C/EBPα binding in progenitor cells and primary MΦ is illustrated for the *PU.1* and *Cebpb* genes ([Figure 7](#fig7){ref-type="fig"}C) as well as for the *Tlr4* and *Ctsd* genes.

Together, our observations indicate that, within the hematopoietic system, the combination of *Pu.1*, *Cebpa*, and *Cebpb* determines the activity of the two types of prospective macrophage enhancers and, hence, the expression of adjacent genes in a manner that recapitulates C/EBPα-induced transdifferentiation.

Discussion {#sec3}
==========

Our study of C/EBPα-induced pre-B-cell-to-macrophage transdifferentiation has revealed two types of prospective myeloid enhancers that are activated by C/EBPα. Pre-existing enhancers in pre-B cells are decorated with active enhancer marks and bound in their majority by PU.1, while de novo enhancers are free of enhancer activation marks and free of PU.1; C/EBPα simultaneously hyper-activates pre-existing enhancers and newly activates de novo enhancers (summarized in [Figure 7](#fig7){ref-type="fig"}D). These enhancers drive a substantial part of the gene repertoire required for the formation of functional macrophages. Strikingly, we also observed a similar synergy between pre-existing and de novo enhancers during myeloid lineage specification during normal hematopoiesis ([Figure 7](#fig7){ref-type="fig"}E).

The finding that pre-existing-type myeloid enhancers drive low-level expression of adjacent myeloid-restricted genes in early hematopoietic progenitors provides a mechanistic explanation for the phenomenon dubbed "lineage priming" ([@bib23]). The observed expression of the myeloid markers lysozyme and CSF-1 receptor in hematopoietic stem cells ([@bib28; @bib47]) supports this interpretation. The following observations indicate that PU.1 is a key component in the generation of pre-existing myeloid enhancers: (1) most pre-existing enhancers are bound by the factor; (2) PU.1 is expressed in stem and progenitor cells, but downregulated in T cells and Erys ([@bib2; @bib27; @bib29]), and this strongly correlates with the distribution of pre-existing myeloid enhancers and the expression of nearby genes; and (3) overexpression of PU.1 in fibroblasts partially activates myeloid genes associated with pre-existing enhancers ([Figure 2](#fig2){ref-type="fig"}G) and C/EBPα further enhances their expression, while C/EBPα alone has no effect ([@bib15]).

However, it is likely that, in addition to PU.1, other TFs participate in the initiation of the establishment of pre-existing enhancers and the activation of de novo enhancers. Thus, C/EBPα sites also were enriched for the RUNX motif, in line with the finding that during myelopoiesis Runx1 binds transiently to the URE element of the *Pu.1* gene to establish open chromatin, permitting the binding of PU.1 ([@bib22]). In addition, it is possible that the *Fos* gene acts as a downstream effector, as it is directly regulated by C/EBPα and we observed enrichment of AP-1 motifs in C/EBP-bound sites where it might co-operate with C/EBPs.

The weakly active pre-existing myeloid enhancers in hematopoietic progenitors appear to be in a stand-by state that can be fully activated by changes in the bone marrow microenvironment either during development or in adult life, such as after infections with pathogens. These signals may in turn increase the levels of PU.1, C/EBPα, and C/EBPβ expression. Thus, for example, bacteria or inflammatory stimuli can upregulate *Pu.1* expression in hematopoietic stem cells through the activation of M-CSF, a cytokine that in turn activates the CSF-1 receptor ([@bib28]). In addition, the yeast *Candida albicans* can induce emergency granulopoiesis in hematopoietic progenitors through upregulation of C/EBPβ ([@bib20]). Therefore, the ectopic expression of C/EBPα/β to induce transdifferentiation of pre-B cells might mimic processes that are normally triggered in hematopoietic progenitors by developmental cues or pathogens.

Surprisingly, a subset of pre-existing enhancers appears to be bi-functional. In B cells this subset is bound by the B cell TF Ebf1, typically in combination with PU.1, resulting in low-level expression. Binding of C/EBPα further activates these genes, raising the possibility that their products are themselves bi-functional. The *Cebpb* gene illustrates this scenario as its putative 88-kb upstream enhancer is bound by Ebf1, which is eventually replaced by C/EBPα during the conversion into myeloid cells. In addition the factor is required for the function of both B cells and macrophages ([@bib6; @bib39]). However, whether the 88-kb site is the physiologically most relevant *Cebpb* enhancer is unknown.

Previous work on TF combinations that induce cell fate conversions have postulated two alternative models as follows: (1) a symmetric collaboration between various TFs acting as pioneer factors, exemplified by Oct4, Sox2, and Klf4 that act during iPSC reprogramming ([@bib37]); and (2) a hierarchical model, exemplified by Ascl1 acting as a pioneer for the subsequent binding of Brn2 and Myt1l during induced neuronal transdifferentiation ([@bib43]). Here we propose a mixed model, where the key lineage-instructive factors exert dual roles as both pioneer and secondary factors. The conclusion that C/EBPα can act as a pioneer factor is based on the observation that it binds to chromatin regions free of activating histone marks and to a nucleosome-dense region within de novo enhancers, agreeing with the reported pioneer activity of C/EBPβ ([@bib36]). It is possible that PU.1 also can act as a pioneer factor, as it is one of the earliest lineage-instructive factors expressed in the hematopoietic system ([@bib13]), and on its own can induce the expression of myeloid genes in non-hematopoietic cells.

In conclusion, our work revealed that the collaboration between an exogenous and an endogenous lineage-instructive TF (C/EBPα and PU.1) leads to the activation of pre-existing and de novo myeloid enhancers during transdifferentiation, resulting in macrophage differentiation. Interestingly, this mechanism recapitulates the way endogenous C/EBP factors and PU.1 collaborate to induce myeloid differentiation during normal hematopoiesis. It will be interesting to determine whether conversions of other cell types driven by TFs likewise recapitulate developmental processes that result from the superimposition of complementary enhancer types.

Experimental Procedures {#sec4}
=======================

Cell Culture, Retroviruses, and shRNA Constructs {#sec4.1}
------------------------------------------------

The origin of the HAFTL pre-B cell line, its derivatives C10 (C/EBPαER-GFP) and C11 (C/EBPαER-hCD4), and induction of transdifferentiation (treatment with 100 uM β-est and grown in the presence of 10 nM Il-3 and 10 nM CSF-1) have been described previously ([@bib4; @bib45]). The shC/EBPβ-KD07 directed to the ORF of *Cebpb* was purchased from Sigma (Mission shRNA System) in a pLKO.1-puro lentiviral backbone. An shRNA against PU.1 cloned into LMP-GFP virus (Open Biosystems) was a gift from Dr. M. Sieweke ([@bib34]). The 3T3 cell culture conditions and the PU.1-GFP construct have been described previously ([@bib15]). Phagocytosis of yeast was performed as described previously by [@bib32]. To test for statistical differences of C/EBPα binding after knockdown of PU.1, we applied the Student's t test, one-tailed, alpha level (0.05).

FACS {#sec4.2}
----

FACS experiments were performed as described previously ([@bib4]) using conjugated antibodies against Cd19 (550992) and Cd11b (552850) and combined with blocking antibody (553142) from BD Pharmingen. Unstained cells or an isotype control antibody (553932, BD Pharmingen) were used as a negative control.

ChIP, ChIP-Seq, and MNase-Seq Experiments {#sec4.3}
-----------------------------------------

ChIP experiments were performed as described previously ([@bib41]). DNA libraries were prepared using Illumina's reagents and instructions. Nucleosome positioning was determined by MNase digestion using a modification of a published method ([@bib5]). All libraries were sequenced on the Illumina GA IIx or Hiseq2000 sequencer.

Processing of ChIP-Seq and MNase-Seq Data {#sec4.4}
-----------------------------------------

High-throughput Illumina sequencing data were base-called using the Illumina pipeline, and sequencing reads were aligned to the mouse genome (mm9) using either the Illumina Eland alignment tool or Bowtie ([@bib26]) without mismatches. Aligned sequences were filtered to remove identical sequence tags and sequence tags not aligning uniquely to the mouse genome. To detect enriched regions, we used HOMER (<http://homer.salk.edu/homer/ngs/index.html>) ([@bib19]; and see [Table S1](#mmc2){ref-type="supplementary-material"}). See the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for further details. To test for statistical differences in the level or reduction of coverage between sets of regions, we applied the Wilcoxon rank-sum test, two-tailed, alpha level (0.05).

Binding Site Annotation, Motif Analysis, and Gene Expression {#sec4.5}
------------------------------------------------------------

Position of non-redundant regions relative to TSS of nearest gene (RefSeq mm9) was based on center position and calculated by in-house Perl scripts. For a subset of genes, the median expression level was calculated, and, to test for statistical differences in gene expression levels between sets of genes, we applied the Wilcoxon rank-sum test, two-tailed, alpha level (0.05). Gene expression values in hematopoietic cells ([@bib27]) were normalized by dividing each presented mRNA value by the average mRNA of all listed genes per cell type. To annotate genes for enrichment of GO terms, we employed David with standard settings ([@bib24]). Motif discovery within selected regions was performed using HOMER ([@bib19]).

Gene Expression Analyses by qRT-PCR {#sec4.6}
-----------------------------------

To analyze mRNA levels of selected genes in either C10 cells induced with β-est or 3T3 cells overexpressing PU.1, we extracted RNA using trizol and reverse transcribed it with GeneAmp RNA PCR (Applied Biosystems). SybrGreen PCR Master Mix (Applied Biosystems) was used for amplification and detection of cDNAs, and PCR reactions were carried out with the AB7900HT detection system (Applied Biosystems). To test for statistical differences in mRNA levels, we applied the Student's t test, one-tailed, alpha level (0.05).

Accession Numbers {#app1}
=================

The accession numbers for the ChIP-seq data reported in this paper are GEO: [GSE53173](ncbi-geo:GSE53173){#intref0015}, [GSE53362](ncbi-geo:GSE53362){#intref0020}, and [GSE53460](ncbi-geo:GSE53460){#intref0025} for chromatin marks, factor binding, and MNase, respectively.

Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S6Table S1. Summary of Peak Calling Statistics of TFs and Chromatin Marks by HOMERTable S2. Peak Characteristics, Annotation, and Gene Expression of Nearest Genes of C/EBPα-Enriched Regions in Induced MacrophagesTable S3. Genomic Coordinates of University of California, Santa Cruz, Screenshot Examples and Tested Loci for ChIP, RefSeq mm9/10Table S4. Primer SequencesMovie S1. Transdifferentiation in ActionThe video shows a culture of C10 cells labeled with GFP surrounded by red fluorescent yeast (*Candida albicans*). As the TF C/EBPα is activated within the B cells, these aggregate and turn into macrophages that ingest the yeast, so that 51 hr after activation all pathogens were eaten. The microscope used for the acquisition was a Zeiss Cell Observer HS.Document S2. Article plus Supplemental Information
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![Upregulation of *Cebpb* and *Pu.1* Genes by C/EBPα and Effects of Their Knockdown on Transdifferentiation\
(A) Expression of endogenous *Pu.1*, *Cebpb*, and *Cebpa* RNA after β-Est induction of C10 cells as measured by qRT-PCR. Data are represented as mean ± SEM (independent triplicates) expressed as the fold induction relative to uninduced pre-B cells.\
(B) FACS plots of C11 pre-B cell carrying either a scrambled short hairpin knockdown construct (control) or constructs against C/EBPβ, PU.1, or both, and induced by β-est treatment. See also [Figure S1](#mmc1){ref-type="supplementary-material"}C.\
(C) Percentage of upregulated or downregulated genes (\>2-fold) within defined windows around C/EBPα sites. Dotted lines indicate that 70% of all upregulated genes are within 100 kb of a C/EBPα-binding site.\
(D) Significantly enriched sequence motifs at C/EBPα-binding sites as determined by HOMER.\
(E) Heatmaps visualizing C/EBPα, C/EBPβ, and PU.1 binding in pre-B cells and iMΦ. Window, 3 kb; bin, 10 bp. See also [Figure S1](#mmc1){ref-type="supplementary-material"}E.\
(F) Venn diagram showing the intersection of C/EBPα sites in iMΦ (n = 10,849) and primary MΦ (n = 62,814).\
(G) Screenshots of C/EBPα, C/EBPβ, and PU.1 binding at selected enhancers in C10 cells and of C/EBPα in primary MΦ. Arrows indicate TSS, length of ORF, and direction of transcription. See also [Figure S1](#mmc1){ref-type="supplementary-material"}I.](gr1){#fig1}

![Prospective Myeloid Enhancers with Either Pre-existing or De Novo Configurations in Pre-B Cells\
(A) Heatmaps visualizing H3K4Me1, H3K27Ac, P300, H3K27Me3, and PU.1 in pre-B cells and C/EBPα binding in iMΦ. Center of C/EBPα binding, 0; window, 6 kb; bin, 100. See also [Figures S2](#mmc1){ref-type="supplementary-material"}B--S2D.\
(B) As in (A), visualizing H3K4Me1, H3K27Ac, and PU.1 in primary mature B cells.\
(C and D) Screenshots of C/EBPα and PU.1 binding in C10 cells (0 and 48 hpi) and primary pre-B cells (0 and 18 hpi) at pre-existing (C) and de novo enhancers (D).\
(E) Distribution of genes nearest pre-existing or de novo enhancers marked with bivalent (H3K4Me3, H3K27Me3), active (H3K4Me3), or repressed (H3K27Me3 or no marks) promoters. See also [Figure S2](#mmc1){ref-type="supplementary-material"}E.\
(F) Distribution of mRNA levels of upregulated genes nearest to either pre-existing (n = 318) or de novo (n = 103) enhancers in pre-B cells (C10) and primary pre-B cells. Statistical analysis by Wilcoxon rank-sum test, ^∗∗^p \< 0.001.\
(G) Expression of genes nearest pre-existing or de novo enhancers in 3T3 cells or 3T3 overexpressing PU.1 by qRT-PCR. Data are represented as mean ± SEM (independent triplicates) and expressed as the fold induction relative to 3T3 cells. Statistical analysis by Student's t test, ^∗^p \< 0.05.](gr2){#fig2}

![Binding of the B Cell TF Ebf1 to Pre-existing Enhancers\
(A) Frequency of Ebf1 motif within pre-existing and de novo C/EBPα-binding sites by HOMER.\
(B) Genomic distribution of Ebf1-binding events (n = 6,627) relative to the TSS in C10 cells. ORF, open reading frame.\
(C) Significantly enriched sequence motifs at Ebf1-binding sites, as determined by HOMER.\
(D) Number of C/EBPα sites bound by Ebf1 for each enhancer type.\
(E) Heatmaps, centered on C/EBPα binding in iMΦ, visualizing Ebf1, C/EBPα, and H3K27Ac after the induction of transdifferentiation. Center of binding, 0; window, 6 kb; bin, 100.\
(F) Screenshots of C/EBPα, PU.1, Ebf1, and H3K27Ac ChIP-seq profiles at selected enhancer regions in C10 cells. See also [Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D.](gr3){#fig3}

![C/EBPα Binds to Open and Closed Chromatin\
(A) Kinetics of PU.1, C/EBPα, and C/EBPβ binding at center position of pre-existing (n = 4,711) and de novo (n = 3,424) enhancers at indicated hpi. Statistical analysis by Wilcoxon rank-sum test, ^∗∗^p \< 0.001. See also [Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B.\
(B) C/EBPα and PU.1 binding order on de novo sites (C/EBPα first \[C/EBPα-PU.1\], simultaneously, or PU.1 first \[PU.1- C/EBPα\].\
(C) Screenshots of C/EBPα and PU.1 binding at selected pre-existing or de novo enhancers (10, 30, and 60 min).\
(D and E) C/EBPα binding at pre-existing (D) or de novo (E) enhancers in induced C10 cells knocked down for PU.1. See also [Figure S4](#mmc1){ref-type="supplementary-material"}C. Data are represented as mean ± SEM (independent triplicates). Statistical analysis by Student's t test, ^∗^p \< 0.05. Primer sequences are given in [Table S4](#mmc5){ref-type="supplementary-material"}.\
(F and G) Average MNase profiles at pre-existing (F) and de novo (G) enhancers bound by C/EBPα and PU.1 (shown in blue and brown). Profiles were centered on PU.1 binding in iMΦ and normalized by median subtraction. Window, 6 kb; bin, 1 bp. See also [Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E.](gr4){#fig4}

![Kinetics of Histone Marks, P300 Binding, and Gene Expression Associated with Myeloid Enhancers\
(A) Heatmaps visualizing H3K4Me1, H3K27Ac, P300 binding, and H3K27Me3 at pre-existing and de novo enhancers at different hpi of induced C10 cells. Window, 6,000 bp; bin, 100. See also [Figure S5](#mmc1){ref-type="supplementary-material"}A.\
(B) Quantification of H3K4Me1, H3K27Ac, and P300, as in (A). Bins with the highest coverage are shown.\
(C) Quantification of H3K27Me3, as in (A), except values at the center position are shown. See also [Figure S5](#mmc1){ref-type="supplementary-material"}B.\
(D) Screenshots of selected enhancers showing C/EBPα, PU.1, P300, H3K4Me1, H3K27Ac, and H3K27Me3 profiles in C10 cells. See also [Figure S5](#mmc1){ref-type="supplementary-material"}C.\
(E and F) Distribution of mRNA levels of upregulated genes nearest to either pre-existing (n = 318) or de novo (n = 103) enhancers during transdifferentiation of C10 cells and primary pre-B cells is shown. See also [Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E.](gr5){#fig5}

![Distribution of Active Myeloid Enhancers during Hematopoietic Differentiation\
(A) Cartoon depicting blood cell lineage specification.\
(B and C) Percentage of pre-existing and de novo macrophage enhancers intersecting with enhancers decorated with H3K27Ac in different hematopoietic progenitors and differentiated cell types. The size of the circles relative to circles in (A) indicates the percentage of representation. See also [Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B.\
(D) Heatmaps visualizing H3K27Ac and H3K4Me1 decoration at pre-existing and de novo enhancers during myeloid differentiation. Window, 6,000 bp; bin, 100.\
(E) As in (D), but for T cells.\
(F) Screenshots of H3K4Me1 and H3K27Ac profiles at selected C/EBPα-bound enhancers of *Pu.1* and *Cebpb* in the indicated hematopoietic cell types.\
(G) Median mRNA levels of genes nearest either pre-existing (green lines; n = 318) or de novo (red lines; n = 103) enhancers in different hematopoietic stem/progenitors and differentiated cells. Statistical analysis by Wilcoxon rank-sum test, ^∗∗^p \< 0.001. See also [Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D.](gr6){#fig6}

![Expression Kinetics of Genes Associated with Pre-existing and De Novo Enhancers during Hematopoiesis\
(A) mRNA levels of *Pu.1*, *Cebpa*, and *Cebpb* in different hematopoietic stem/progenitor cell types, based on RNA-seq data ([@bib27]).\
(B) Percentages of pre-existing or de novo enhancers bound by C/EBPα in early hematopoietic progenitors (Lin- Sca-1+ Kit+, LSK cells), GMPs, or primary MΦ.\
(C) Screenshots of C/EBPα bound to selected enhancers of *Pu.1*, *Cebpb*, *Tlr4*, and *Ctsd* in the indicated hematopoietic cell types. Pre-ex., pre-existing.\
(D) Pre-existing and de novo myeloid enhancers in pre-B cells and iMΦ, showing PU.1 occupancy, binding sites targeted by incoming C/EBPα (curved arrows), enhancer states, and gene expression. Nucleosomes are indicated by light blue balls.\
(E) Artist's rendering of the trajectory of activated pre-existing enhancers within the hematopoietic lineage tree (in green) and de novo enhancers (in red). The arrow depicts how C/EBPα short circuits the two trajectories when expressed in pre-B cells.](gr7){#fig7}
